NewsRelease

JournalArticle Describes New Strategies to Categorize Blood for ProteomicBiomarker Discovery

MONMOUTHJUNCTION, NJ, April 23, 2020 – A journal article by Biotech SupportGroup, with co-authors from Vanderbilt University Medical Center andRutgers Proteomics Center, describes new strategies for proteomicinvestigation of blood components.

Citationis:

KurucM, Zheng H, Sowerhardy A, Avadhani S, Roy D, et al. (2020) New Strategies to Categorize Blood for Proteomic Biomarker Discovery.Proteomics & Bioinformatics, 2(2): 90-107.

Althoughmuch effort has gone into genomic sequencing to define disease, thedownstream products of gene sequences-proteins, nevertheless remainthe master regulators of biology. Many proteins are measurable inblood, making it a rich resource for biomarkers. Yet for reasonslargely unrelated to analytical limitations, this resource remainslargely untapped. In this review, we describe how chronic illnessmanifests itself in blood and how we might study innate immunity tounderstand mechanisms that can potentially translate into newbiomarkers and therapeutic modalities.

Wedraw upon BSG's knowledgebase of proteome information reportableafter using depletion or enrichment products in LC-MS/MS workflowsand how this knowledge can be utilized in new strategies forbiomarker discovery from blood samples. We note that BSG’s productshave simply and efficiently reduced the complexity of the serumproteome allowing for cost-effective workflows, without the use ofantibody-based depletion methods. Finally, we discuss how patterns ofSerpins, a superfamily of protease inhibitors, may serve as asurrogate measure of the progressive stages of the innate immunesystems’ response to both infectious and noninfectious disease.This convergence of strategies and LC-MS/MS technologies has made thetask immediately available to investigators to now develop the nextgeneration of molecular tests for more precise and personalized treatment of patients.

SwapanRoy, Ph.D., President and Founder of Biotech Support Group, concursstating “Proteomics started with annotation and Venn diagrams butnow the field demands robust quantitation. This has been our focus;how to address quantitative differences between proteins in bloodsamples representing a challenge or disease state, vs. samplesrepresenting a normal or control state. Ultimately, biomarkersderived from blood provides the most useful clinically actionablebiomarkers so that is why our product line is focused on all bloodcompartments, both cellular and extracellular. We argue in thisreport for characterization of the innate immune response, asproteins derived from it imparts a wide range of effects ininfectious and non-infectious disease. The innate response proteomealso is in the sweet spot of LC-MS analysis. Furthermore, anover-exuberant innate immune response is now one of the challengesthe world faces with COVID-19 induced acute respiratory distresssyndrome (ARDS). We hope with the strategies described in thisreport, we can find and develop biomarkers to not only bettercharacterize disease but provide a better understanding of how theinnate immune response becomes dysregulated in chronic disease, withconsequences for acute disease. From this, we hope to gain furtherinsight so that healthcare professionals can develop new andsometimes repurpose approved therapies, to address many diseases;COVID-19 being one of many with a highly engaged inflammatorycomponent.

Formore information on the BSG complete line of Albumin & IgGRemoval products, visit:https://www.biotechsupportgroup.com/Articles.asp?ID=451

AboutBiotech Support Group LLC

Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group (BSG) develops methods for costeffective and efficient sample prep essential for these expandingmarkets. Following a tiered business strategy, the company continuesits growth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal,and NuGel™ for functional proteomics. From these innovations, thecompany has acquired knowledgebase and biomarker intellectualproperty assets that support discoveries of protein markers fromblood, with special emphasis on early detection and personalizedmedical decisionsfor cancer patients.

Formore information, go tohttp://www.biotechsupportgroup.com.For business development, contact Matt Kuruc at[email protected]